Nurix Therapeutics, Inc. - Common stock (NRIX) analyst actions
Rating and price-target actions on NRIX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NRIX overview →
2 measured NRIX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader | Press release | -1.56% | +4.18% | |
| Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | Press release | -3.21% | -9.07% |
Keep exploring
More NRIX: earnings → · SEC filings → · NRIX overview →